Selected article for: "disease role and risk factor"
Author: Varagic, Jasmina; Ahmad, Sarfaraz; Nagata, Sayaka; Ferrario, Carlos M.
Title: ACE2: Angiotensin II/Angiotensin-(1-7) balance in cardiorenal injury
  • Cord-id: etzzlryf
  • Document date: 2014_2_9
    • ID: etzzlryf
    Snippet: Our current recognition of the renin-angiotensin system is more convoluted than originally thought due to the discovery of multiple novel enzymes, peptides, and receptors inherent to this interactive biochemical cascade. Over the last decade angiotensin converting enzyme 2 (ACE2) has emerged as a key player in the pathophysiology of hypertension and cardiovascular and renal disease due to its pivotal role in metabolizing vasoconstrictive/hypertrophic/proliferative angiotensin II into favorable a
    Document: Our current recognition of the renin-angiotensin system is more convoluted than originally thought due to the discovery of multiple novel enzymes, peptides, and receptors inherent to this interactive biochemical cascade. Over the last decade angiotensin converting enzyme 2 (ACE2) has emerged as a key player in the pathophysiology of hypertension and cardiovascular and renal disease due to its pivotal role in metabolizing vasoconstrictive/hypertrophic/proliferative angiotensin II into favorable angiotensin-(1-7). This review addresses a considerable advancement in research on the role of tissue ACE2 in development and progression of hypertension and cardiorenal injury. We also summarize the results from recent clinical and experimental studies suggesting that serum or urine soluble ACE2 may serve as a novel biomarker or independent risk factor relevant for diagnosis and prognosis of cardiorenal disease. Recent proceedings on novel therapeutic approaches to enhance ACE2/angiotensin-(1-7) axis are also reviewed.

    Search related documents:
    Co phrase search for related documents
    • absence presence and active site: 1, 2, 3, 4, 5, 6, 7, 8
    • absence presence and activity expression: 1, 2, 3
    • absence presence and activity protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • absence presence and additional study: 1, 2, 3, 4
    • absence presence and additional support: 1
    • ace inhibitor and active site: 1, 2
    • ace inhibitor and active site domain: 1
    • ace inhibitor and activity expression: 1, 2, 3, 4
    • ace inhibitor and activity protein: 1, 2, 3, 4
    • ace similar and active site: 1
    • active site and additional study: 1, 2
    • active site and additional support: 1, 2
    • activity protein and additional study: 1